Clinical Trials Browser

Phase 1/2 × Melanoma × tebentafusp × Clear all

NCT02535078 2024-07-24

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Phase 1/2 Withdrawn

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT02570308 2023-03-21

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

Phase 1/2 Completed

146 enrolled 26 charts

Uveal Melanoma, Melanoma